一种通过过表达PD1-CD3ζ重组蛋白受体提高CAR-T细胞抗肿瘤疗效的方法
By overexpressing the PD1-CD3ζ recombinant protein receptor in CAR-T cells, the problem of insufficient efficacy of CAR-T cells in the treatment of solid tumors was solved, and a significant anti-tumor effect on solid tumors was achieved.
CN122404577APending Publication Date: 2026-07-17THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV
- Filing Date
- 2026-06-17
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing CAR-T cell therapy is effective in treating hematologic malignancies, but its efficacy in treating solid tumors has not yet achieved a substantial breakthrough, and the relapse rate is relatively high.
Method used
By overexpressing the PD1-CD3ζ recombinant protein receptor in CAR-T cells, a novel "armed" CAR-T cell was constructed, which utilizes PD-L1-mediated inhibitory signals to convert them into activation signals to enhance anti-tumor efficacy.
Benefits of technology
It significantly enhanced the anti-tumor efficacy of CAR-T cells against solid tumors, and improved cell survival, infiltration ability and killing function.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404577A_ABST
Abstract
本发明公开了一种通过过表达PD1‑CD3ζ重组蛋白受体提高CAR‑T细胞抗肿瘤疗效的方法。本申请在CAR‑T细胞中过表达一种重组融合受体PD1‑CD3ζ。该受体能够将肿瘤微环境中PD‑L1介导的抑制性信号转化为CAR‑T细胞的激活信号，构建一种“武装型”新型CAR‑T细胞，显著增强其对实体瘤的抗肿瘤疗效。
Need to check novelty before this filing date? Find Prior Art